News Category
Regentis Biomaterials reports progress in its Phase III GelrinC trial for knee cartilage repair and receives European approval for a manufacturing pro...
Quantum BioPharma's Lucid-MS, a first-in-class drug that protects and rebuilds myelin, has received FDA clearance for a Phase 2 trial that could trans...
TransCode Therapeutics names John Tattory as interim CFO following Tom Fitzgerald's retirement, bringing extensive financial leadership to guide the c...
VERAXA Biotech's appointment of Dr. Christoph Erkel as chief scientific officer strengthens its leadership as it advances its BiTAC® T-cell engager an...
Quantum BioPharma's FDA clearance for a phase 2 trial of Lucid-MS, a first-in-class myelin-repair therapy, could transform the multibillion-dollar mul...
Quantum BioPharma's Lucid-MS, a first-in-class PAD2 inhibitor, has received FDA clearance to begin a Phase 2 trial for multiple sclerosis, potentially...
Quantum BioPharma's FDA clearance for a phase 2 trial of Lucid-MS represents a historic first in multiple sclerosis treatment, potentially unlocking a...
Helus Pharma's CEO will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference, highlighting the company's advanced clinica...
Onco-Innovations' CMO detailed the company's novel PNKP-targeting drug candidate ONC010, which uses synthetic lethality and nanoparticle delivery to p...
Quantum BioPharma's Lucid-MS, a first-in-class non-covalent PAD2 inhibitor, has received FDA clearance to begin a Phase 2 trial in multiple sclerosis,...
American Fusion Inc. has moved its Texatron fusion program into active testing, achieving peak confinement pressures of approximately 100,000 atmosphe...
Kairos Pharma's CEO presentation at a major investment conference underscores the company's progress in developing ENV-105, an antibody aimed at rever...
Nutriband's CEO participation at the Nasdaq LaB summit underscores the importance of its AVERSA technology in addressing opioid abuse, potentially inf...
Silo Pharma's participation in the IPAC-RS 2026 Nasal Innovation Forum underscores its commitment to advancing SPC-15, a nose-to-brain therapy for PTS...
Quantum BioPharma's FDA clearance to advance Lucid-MS into Phase 2 trials marks a significant milestone for a novel myelin-repair approach to multiple...
Quantum BioPharma's multiple sclerosis drug candidate Lucid-MS has received FDA clearance to begin a Phase 2 trial, a rare milestone for a micro-cap b...
Helus Pharma's CEO participation in a major investment conference highlights the company's progress in developing novel serotonergic agonists for ment...
GeoVax applauds the new global mpox vaccine stockpile and highlights its GEO-MVA candidate's readiness to support a diversified supply.
Voyageur Pharmaceuticals has met the first milestone under its Bayer collaboration, receiving USD $1 million to advance a feasibility study for domest...
Greenland Mines is spinning off its biotech division in Q4 2026 to focus on rare earths, following the completion of its Sarfartoq acquisition and a p...
VERAXA Biotech's appointment of Raju Willener as CFO signals a strategic move to enhance its capital strategy and support the advancement of its oncol...
Scinai Immunotherapeutics has strategically exited its PC111 license with PinCell to concentrate resources on its NanoAb platform and CDMO business, a...
Onco-Innovations Ltd. strengthens its clinical foundation for ONC010, a nanoparticle-encapsulated PNKP inhibitor, through manufacturing milestones, IN...
OS Animal Health's presentation at the Moody Capital conference underscores its strategic push to secure USDA conditional approval for OST-HER2, a pro...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS, a first-in-class myelin repair candidate, marks a pivotal step toward treating the ...
Quantum BioPharma's FDA clearance for a phase 2 trial of Lucid-MS marks a potential breakthrough in treating multiple sclerosis by targeting myelin re...
NanoViricides' registration of its Phase II Ebola trial in the DRC marks a critical step in evaluating NV-387 as a potential treatment for Ebola, with...
Greenland Mines (NASDAQ: GRML) plans to spin off its biotech division in Q4 2026, following Nasdaq approval and completion of the Sarfartoq acquisitio...
The FDA has cleared Quantum BioPharma's IND application to begin a Phase 2 trial of Lucid-MS in multiple sclerosis, a key milestone for the first-in-c...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS, a novel remyelination agent, marks a significant step in MS treatment and draws ana...
Quantum BioPharma's FDA clearance to initiate a Phase 2 trial of Lucid-MS marks a pivotal step toward a novel therapy for multiple sclerosis that targ...
The LGL Group's participation in the Moody Capital Solutions conference underscores its dual-platform strategy aimed at compounding shareholder value ...
Interlink Electronics' participation in the Moody Capital conference underscores its strategic focus on expanding into high-growth markets and engagin...
The Moody Capital 2026 Disruptive Growth & Life Sciences Conference is strategically timed to address significant small- and mid-cap activity in life ...
Tonix Pharmaceuticals elevates Thomas Englese to Chief Commercial Officer to lead commercialization efforts for its fibromyalgia treatment TONMYA and ...
AcroMeta Group Limited announced a strategic partnership with Macro HRD SG Pte. Ltd. to enter the ambient temperature cellular logistics market, inclu...
Onco-Innovations has achieved significant preclinical milestones for its PNKP inhibitor ONC010, including high-purity API production and an Australian...
VERAXA Biotech's appointment of Raju Willener as CFO underscores its commitment to advancing its BiTAC technology and oncology pipeline through strate...
BioVersys will present a corporate overview at the H.C. Wainwright conference, highlighting its clinical-stage antibacterial programs targeting multid...
OS Therapies' participation at the Moody Capital conference comes as it approaches key FDA and U.K. regulatory decisions and data readouts for its lea...
A Swiss-led preclinical study reveals that administering immunotherapy prior to surgical resection significantly improves glioblastoma treatment outco...
Tonix Pharmaceuticals' participation in the Cantor 2026 Global Healthcare Conference highlights its strategic focus on CNS and immunology advancements...
NurExone Biologic's participation in the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference highlights its advancing exosome-ba...
CNS Pharmaceuticals' Chief Business Officer details the company's focus on in-licensing and acquiring oncology and neurology assets to build a pipelin...
Hong Kong's new SEAM@InnoHK research cluster aims to solidify the city's role as a global I&T hub by focusing on sustainable development, energy, and ...
Quantum BioPharma's lead candidate Lucid-MS for progressive multiple sclerosis earns a 'Buy' rating from Rodman & Renshaw, highlighting its potential ...
NanoViricides is progressing its measles treatment NV-387 to Phase II clinical trials, leveraging FDA designations and strong preclinical data as meas...
TransCode Therapeutics announced peer-reviewed preclinical results showing its lead candidate TTX-MC138 accumulates in metastatic bone lesions, inhibi...
